– Generated Record Net Revenue of $123.5 Million – – BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million – – Raises Full Year Adjusted EBITDA Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Aug.

STOUGHTON, Mass. , July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 2022 .

STOUGHTON, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach

- Generated Net Revenue of $83.8 Million - - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Resolved All Opioid-Industry Litigation - - Reaffirms 2022 Financial Guidance - - Conference Call Scheduled for Today at 4:30 p.m.

STOUGHTON, Mass. , April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET .

STOUGHTON, Mass. , April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in the following investor conference: 21 st Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass. , April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022 .

– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA Expected in the Range of $235.0 million to $250.0 million – STOUGHTON, Mass.

STOUGHTON, Mass. , March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United

STOUGHTON, Mass. , March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to

– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million , Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – – Cash Balance of $186.4 Million – – Conference Call Scheduled for Today at 4:30

- Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - -   Addition of BELBUCA ® Provides a Second Growth Driver and ELYXYB ™ Establishes Foothold in Neurology - -

STOUGHTON, Mass. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 , at 4:30 p.m. Eastern Time . The Company will discuss its fourth quarter and